Insights from the “Tinker to Treasure” Webinar The development of radiopharmaceuticals offers tremendous potential for both the diagnosis and treatment of disease. However, turning early-stage research into a market-ready produ...
Blogs
Behind the Scenes of an FDA Type C Meeting: A Case Study in Using Gap Analysis to Align Nonclinical Strategy in a Rare Pediatric Disease
By Tom Hallam, Ph.D., MBA For small pharma companies navigating the road to US market approval, the right nonclinical regulatory strategy, built with expert consulting and scientific guidance, can mean the difference between ef...
Why Strategic Statistical Consulting is Essential & The Role of a Statistician in FDA Meetings
When preparing for a meeting with the FDA, most Sponsors focus on regulatory affairs, clinical leads, or medical officers. However, one role that is becoming increasingly central and often overlooked is the statistician. Whethe...
How Do I Determine Good Regulatory Guidance?
by Lisa Jenkins VanLuvanee, Ph.D. For small biotech and medical device companies without internal regulatory experts, knowing whether you’re getting the right advice can be a real challenge. In this interview, Dr. Lisa Je...
Everyone is Talking About HEOR! What Exactly is it and Why is it Relevant to You?
By Dr. Randy Goodman Ph.D., MHA, FACHE, PMP, BCMAS HEOR stands for Health Economics and Outcomes Research. It is a science that combines health economics, which focuses on the allocation of healthcare resources, and outcomes re...
Leveraging Breakthrough Therapy Designation (BTD) for Gene Therapy Development: Key Lessons from a Case Study
by Dr. Jason Mercer, Ph.D., RAC and Strategic Program Innovator FDA’s Breakthrough Therapy Designation (BTD) program offers sponsors a powerful opportunity to expedite development of promising therapies for serious or life-thr...
The Nonclinical Development Path for Radiopharmaceutical Drugs
By Dr. Bill F. Hodnick, DABT Microdose radiopharmaceutical drugs are a unique class of drugs characterized by single or infrequent administration of a very small dose (microdose) of a radiolabeled compound. These radiopharmaceu...
Key Challenges with Orphan Drug Development for Rare Disease Treatments
By Lisa Jenkins VanLuvanee, Ph.D. Per the US FDA, orphan drugs address rare diseases affecting fewer than 200,000 people in the United States. Developing these therapies presents challenges beyond typical drug development. The ...
Facet is Proud to be a 2025 SNMMI Mars Shot Research Fund Donor
Facet Life Sciences contributed to and proudly supports the 2025 Mars Shot program, a Society of Nuclear Medicine and Molecular Imaging (SNMMI) initiative that provides funding to developers using nuclear medicine to find novel...
Facet Life Sciences Announces Partnership with Nucleus as Official Regulatory Partner
Facet Life Sciences specializes in guiding life science companies through the complex journey of drug, biologic, and medical device development and registration with the US FDA. Facet is pleased to announce the company’s role a...
Navigating Pre-IND Meetings: A Strategic Guide
When developing a new drug, early engagement with FDA through a Pre-Investigational New Drug (Pre-IND) meeting can set the stage for a smoother regulatory process. This meeting is essential to avoid clinical holds and prevent c...
Navigating the Pre-BLA Meeting Process: Securing a Clear Pathway to Success
Preparing for a Pre-Biologics License Application (Pre-BLA) meeting with FDA is a pivotal step in the regulatory journey for sponsors seeking to bring a biologic product to market. This meeting provides an invaluable opportunit...
gET sOCIAL